Navigation Links
New compound reduces stroke damage

A group of German scientists has synthesized a new compound that dramatically decreases the damage to neurons in rats demonstrating stroke symptoms. The research appears as the "Paper of the Week" in the May 26 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.

Stroke is the third leading cause of death in the United States and the most common cause of adult disability. An ischemic stroke occurs when a cerebral vessel occludes, obstructing blood flow to a portion of the brain. Currently, there is only one approved stroke therapy, tissue plasminogen activator, which targets the thrombus within the blood vessel. Because of the lack of available stroke treatments, neuroprotective agents have also generated as much interest as thrombolytic therapies.

The immunosuppressive drug FK506 (also known as Tacrolimus or Prograf®) is often administered to patients receiving transplants to prevent organ rejection. Dervatives of the drug are also commonly used in the treatment of autoimmune diseases. FK506 inhibits T-cell activation by binding to members of the FK506-binding protein (FKBP) family. Interestingly, FK506, and several molecules with similar structures, also demonstrate neuroprotective and neuroregenerative effects in a wide range of animal models mimicking Parkinson's disease, dementia, stroke, and nerve damage.

Gunter Fischer and his colleagues at the Max-Planck Research Unit for Enzymology of Protein Folding in Germany have now determined that neuroprotective FK506 derivatives specifically target a receptor called FKBP38. "High FKBP38 activity in neuronal cells triggers mechanisms leading to programmed cell death," explains Fischer. "Inhibition of FKBP38 makes cells more predisposed to survive."

The scientists also synthesized a molecule that specifically inhibits FKBP38 and administered it to rats that were experiencing stroke symptoms. "We developed a lead compound that strongly inhibits FKBP38 leaving other brain FKBP almost untouched under certain conditions," said Fischer. "A strong neuroprotective effect became obvious in an animal model of stroke when the animals were treated with this lead compound."

Fischer and his colleagues found that their compound protected the rats' neurons and also caused neural stem cell proliferation and neuronal differentiation. Diseased animals with motor behavior deficits also showed improvement when they were given the synthetic drug.

These results suggest a potential therapeutic application specific FKBP38 inhibitors in the treatment of neurodegeneration following stroke and a number of other diseases.


'"/>

Source:American Society for Biochemistry and Molecular Biology


Related biology news :

1. Researchers discover chemical compounds that affect plant growth
2. Bacterial genome sheds light on synthesizing cancer-fighting compounds
3. Scientists discover the bodys marijuana-like compounds are crucial for stress-induced pain relief
4. Evolution of taste receptor may have shaped human sensitivity to toxic compounds
5. Novel compounds show promise as safer, more potent insecticides
6. Metal-containing compounds show promise as HIV weapon
7. Natural compound from pond scum shows potential activity against Alzheimers
8. Chemical compound inhibits tumor growth, size in new mouse study
9. Seaweed yields new compounds with pharmaceutical potential
10. Phenolic compounds may explain Mediterranean diet benefits
11. UC Berkeley researchers create a biologically-inspired artificial compound eye
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology: